Leerink Boosts PT on Mallinckrodt (MNK) to $92; Lifts INOMax Expectations
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Leerink is lifting its price target on Outperform-rated Mallinckrodt (Nasdaq: MNK) from $91 up to $92 following recent estimate adjustments.
The firm commented Friday:
We're publishing our updated model to reflect MNK's nuclear imaging divestiture, which is dilutive to EPS but accretive to the growth profile of the company. We are also increasing our INOMax (respiratory) forecasts based on our analysis following encouraging feedback from two MEDACorp neonatology specialists ... we assessed the commercial prospects for MNK’s INOMax franchise, which has beaten consensus expectations in the last 4 qtrs by 8-11%. Based on our checks, INOMax outperformance appears to be driven by two factors: (1) more open attitudes about prescribing in off-label settings where duration of therapy is higher; & (2) a greater shift to unlimited use contracts – which is the highest revenue generating contract type offered by MNK, adopted by ~40% of total institutions. Based on our analysis following the positive feedback, we are increasing our INOMax forecasts by 4-10% between 2017-21E, and our forecasts are now 2% above the Street. Post-nuclear imaging divestiture, our 2-yr and 5-yr EPS CAGR is 9% and 7%, compared to prior forecasts of 6% and 5%, respectively. Key events for MNK include another strong quarter (3Q16 reporting in October), Ph. 4 Acthar lupus data (late '16-early '17 based on clin-trial.gov primary completion date), and potential M&A which can occur anytime.
INOMax uptick keyed to expanded use, possibly due to contract structure that takes price out of the prescribing decision. In the last 4 qtrs, INOMax has meaningfully outperformed consensus sales forecasts, which mgmt. has attributed to a "favorable contracting cycle" and possibly due to more permissive statements about INOMax off-label usage in the medical guidelines. Based on specialist feedback, we continue to hear that INOMax (approved in 1999) is fully penetrated into the more moderate/severe segment of on-label patients suffering from hypoxic respiratory failure (HRF), but that usage has risen in off-label indications including congenital diaphragmatic hernia (CDH) and bronchopulmonary dysplasia (BPD), particularly in patients whose condition is deteriorating and "running out of treatment options." Both specialists we spoke with did not view recent guideline changes as a catalyst for increased use, and both worked at institutions with unlimited INOMax use contracts.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- M&T Bank (MTB) PT Raised to $165 at FBR Capital Following 4Q Beat
- Bassett Furniture (BSET) PT Raised to $28 at Stifel Following 4Q EPS Beat
- UPDATE: Stifel Upgrades Abraxas Petroleum (AXAS) to Buy Amid Emerging Delaware Basin Potential
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!